TOKYO -- Japanese data analysis company Fronteo aims to begin clinical trials as soon as early next year on a diagnostic tool for dementia that uses artificial intelligence.
Fronteo's AI system analyses 5- to 10-minute conversations between a patient and a doctor. The diagnosis itself takes 1 minute. Fronteo hopes to start commercial sales in 2022 of the system, which is designed to minimize stress on both doctors and patients, and help with early diagnosis of dementia.
